Recent studies show that Arf, a bona fide tumor suppressor, also plays an essential role during mouse eye development. Tgfb is required for Arf promoter activation in developing mouse eyes, and its capacity to induce Arf depends on Smads 2/3 as well as p38 Mapk. Substantial delay between activation of these pathways and increased Arf transcription imply that changes in the binding of additional transcription factors help orchestrate changes in Arf expression. Focusing on proteins with putative DNA binding elements near the mouse Arf transcription start, we now show that Tgfb induction of this gene correlated with decreased expression and DNA binding of C/ebpb to the proximal Arf promoter. Ectopic expression of C/ ebpb in mouse embryo fibroblasts (MEFs) blocked Arf induction by Tgfb. Although basal levels of Arf mRNA were increased by C/ebpb loss in MEFs and in the developing eye, Tgfb was still able to increase Arf, indicating that derepression was not the sole factor. Chromatin immunoprecipitation (ChIP) assay showed increased Sp1 binding to the Arf promotor at 24 and 48 hours after Tgfb treatment, at which time points Arf expression was significantly induced by Tgfb. Chemical inhibition of Sp1 and its knockdown by RNA interference blocked Arf induction by Tgfb in MEFs. In summary, our results indicate that C/ ebpb and Sp1 are negative and positive Arf regulators that are influenced by Tgfb. 
Introduction
Arf, a bona fide mammalian tumor suppressor gene transcribed from the Cdkn2a locus, encodes p19
Arf in an alternative reading frame when compared to p16
Ink4a , the first gene found at this chromosomal locus [1] . Mouse p19
Arf is primarily known to physically interact with and block Mdm2, thereby stabilizing p53 and contributing to cancer surveillance [2] . Genetically engineered mice that lack the first coding exon for Arf, but retaining the Ink4a coding sequence, develop spontaneous tumors from as early as two months of age [3] . Although Arf coding sequence can be deleted in mouse and human tumors, in a substantial number the gene is intact but silenced alone or together with INK4A [4, 5] . Therefore, understanding how Arf expression is controlled is relevant to understanding a fundamental mechanism that cancer cells utilize to evade its tumor suppressive activity.
A number of findings indicate that transcriptional control of Arf is the major determinant of p19
Arf protein level and function. Throughout most of the developing mouse embryo, Arf expression is essentially silenced [6] . Indeed, our studies reveal that Arf expression is detectable only in the developing eye and internal umbilical vessels [7] . Global silencing of its expression is mediated by chromatin remodeling proteins such as Bmi1 since the expression of both Arf and Ink4a increase when Bmi1 is deleted in mouse models [8] . In this regard, a long non-coding RNA (ANRIL), transcribed anti-parallel to human ARF and INK4a (and the INK4b gene lying further 59 of ARF/INK4a) [9] acts in cis to foster CBX7 binding to this region in cultured human PC3 cells [10] . Despite evidence for global repression of the Cdkn2a locus, it is also clear that transcription activators contribute to the selective induction or repression of the Arf promoter. Examples include E2Fs 1 and 3 [11, 12, 13, 14] , Dmp1 [15, 16] , AP1 [17] , and Pokemon [18] . FoxO proteins are also implicated as Arf regulators and they appear to act by binding an element in the first Arf intron, far from the transcription start site [19] . It is important to note that many of these conclusions stem from highly tractable cell culture models, but the in vivo relevance is less clear in most cases.
Adding to the concept that Arf must have tissue-specific control is the fact that the gene plays an essential role in eye development [20] . Arf-deficient mice develop persistent hyperplastic primary vitreous (PHPV) that is evident at embryonic day (E) 13.5 and persists in the postnatal period [20] . In this setting, p19
Arf blocks the expression of Pdgfrb, a growth factor receptor that is essential for hyperplastic accumulation of cells in the primary vitreous in the absence of Arf [21] . Tgfb2 is essential for Arf expression in the developing mouse [7] ; and in cultured MEFs, Arf induction by Tgfb depends on activation of TbrII, Smad 2/3, and p38 Mapk [22] . Interestingly, RNA polymerase II binding to the Arf promoter and increased Arf mRNA lag substantially behind activation of these pathways and the binding of Smad 2/3 to the Arf gene [22] . Moreover, Tgfb2 has numerous effects during mouse embryo development whereas Arf expression is principally localized to the primary vitreous [7] . Both findings indicate that other proteins must cooperate with Smad 2/3 to control Arf. Taking advantage of mouse and cell culture-based models, we identify two such cooperating events: de-repression of Arf by C/ebpb down-regulation and loss of promoter binding, and transcriptional activation by Sp1.
Materials and Methods
All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee at the University of Texas Southwestern Medical Center, Dallas, Texas. Methods such as the use of isoflurane for anesthetization of animals were used to minimize suffering during surgeries.
Mice, Cells and Reagents
Arf lacZ/+ [7] mice were maintained in a mixed C57BL/6 6 129/Sv genetic background. 
Real Time RT PCR
Cell pellets were dissolved in 800 ml Trizol (Invitrogen); total RNA was extracted from Trizol solution after addition of chloroform, precipitated with isopropanol, and dissolved in water. Two mg total RNA was use to synthesize cDNA with Superscript III RT kits (Invitrogen) according to the manufacturer's recommendations. Then, quantitative RT-PCR (qRT-PCR) was performed using Fast SYBR Green Master mix and a model 7900 HT Fast Cycler instrument (both from Applied Biosystems). The primers were as follows: Arf: 59-TTCTTGGTGAAGT-TCGTGCGATCC-39 (forward) and 59-CGTGAACGTTGCC-CATCAT CATCA-39 (reverse); C/ebpb: 59-GTTTCGGGACTT-GATGCAAT-39 (forward) and 59-CCCCGCAGGAACATC-TTTA-39 (reverse); Sp1: 59-TCATGGATCTGGTGGT-GATGGG-39 (forward) and 59-GCTCTTCCCTCACTGTC-TTTGC-39 (reverse); Gapdh: 59-TCAACAGCAACTCC-CACTCTTCCA-39 (forward) and 59-ACCCTGTTGCT-GTAGCCGTAT TCA-39 (reverse). Results are pooled from three separate experiments.
Western Blotting and b-Gal Assay
Cells were collected, lysed, separated by SDS-PAGE and transferred to PVDF membrane with 50-100 mg total protein per sample. The membrane was incubated with primary antibody for two hours, washed trice in Tris-Buffered Saline Tween-20 (TBST) for 15 minutes each time; and then incubated with horseradish peroxidase (HRP)-labeled secondary antibody for one hour. After washing in TBST, the membrane was incubated with 2 ml ECL (GE Healthcare Life Sciences) for 5 minutes and visualized by exposure to film. b-galactosidase assays were performed in Arf lacZ/lacZ MEFs as previously described [7] using a commercial kit (Applied Biosystems; Foster City, CA). For western blotting, antibodies directed against the following proteins were utilized: C/ebpb, and Hsc70 (Santa Cruz Biotechnology, Inc; Santa Cruz, CA); phospho-p38 Mapk, and phospho-Smad2 (Cell Signaling Technology; Danvers, MA); and p19
Arf (Abcam Inc; Cambridge, MA). Experimental findings were confirmed in at least two independent experiments, with quantitative data from b-galactosidase assays pooled from all representative experiments.
Laser Capture Microdissection (LCM)
LCM was done as previously described [25] . Briefly, mouse embryos ware harvested at E13.5 for LCM. Embryo heads were immediately embedded in OCT freezing medium without fixation. Fourteen mm thick sections were cut on a CryoStar NX70 cryostat, which were mounted on PEN Membrane Metal Slides (Applied Biosystems) and stained with hematoxylin and eosin (H&E) (Molecular Machines & Industries AG; Glattbrugg, Switzerland). LCM was carried out using an Arcturus Veritas Microdissection System. Cells in the vitreous, lens, and retina were dissected from each eye and collected separately. Samples were pooled from at least 5 microdissected sections from the same embryo. Total RNA was extracted using an Arcturus PicoPure LCM RNA isolation kit (Applied Biosystems) and the expression of specific genes was analyzed with real time RT-PCR as described above.
ChIP Assay
Chromatin immunoprecipitation (ChIP) experiments were performed as previously described [22] . Briefly, wild type MEFs (3610 6 /ChIP) were treated with Tgfb (5 ng/ml) or vehicle for 1.5, 24 or 48 hours. Cells were cross-linked and sonicated, and then subjected to immunoprecipitation using antibodies against C/ ebpb (sc150, Santa Cruz Biotechnology, Inc., Santa Cruz, CA), or Sp1 (sc59, Santa Cruz). Rabbit IgG (sc2027, Santa Cruz) was used as a negative control. Protein A/G sepharose beads (sc2003, Santa Cruz) were used to collect the antibody-chromatin complexes. The beads were washed sequentially with low salt, high salt, LiCl and TE buffers (Upstate ChIP Kit, Millipore) and eluted in 0.1 M NaHCO3, 1% SDS. Cross-linking was reversed by incubation at 67uC overnight, and the genomic DNA was extracted using Qiagen PCR Purification Kit. Quantitative analysis of the precipitated and input DNA was carried out using specific primer sets and Fast SYBR green master mix on a model 7900 HT Fast Cycler instrument (both from Applied Biosystems). The primer sets for proximal promoter regions of Arf were as follows: 59-AGATGGGCGTGGAGCAAAGAT-39 (forward) and 59-ACTGTGACAAGCGAGGTGAGAA (reverse).
siRNA
We purchased siRNA against mouse SP1 (catalog # 74195; Life Technologies, Grand Island, NY). The siRNA was dissolved in 16 siRNA buffer (Dharmacon) and used for transfection (100 nM final concentration). Scrambled siRNA (siGENOME Non-Targeting siRNA #3, Dharmacon) was used as control. 24 hours after the initial transfection, the cells were treated with either Tgfb or vehicle, and they were harvested 48 hours later for western blotting or RT-PCR.
Statistical Analysis
Quantitative data are presented as the mean6S.D. from three or more representative experiments. Statistical significance (p value ,0.05) was calculated using Student's t test.
Results
Recognizing the substantial delay between Smad binding to the Arf promoter and increased synthesis of Arf primary transcript [22] , we considered potential roles for other transcription factors whose function might be influenced by Tgfb. Among those, C/ ebpb was an attractive candidate because previous work had implicated it as an Arf repressor in primary epidermal keratinocytes [26] , and putative consensus DNA binding elements are found within 500 bp 59 to the Arf translation initiation codon ( Figure 1A ). Utilizing chromatin immunoprecipitation (ChIP), we demonstrated that C/ebpb was bound to this region in cultured mouse embryo fibroblasts (MEFs) at passage 3 (YZ and SXS, unpublished data).
We next investigated whether Tgfb influenced the binding of endogenous C/ebpb to the Arf promoter. We previously established that Smad 2/3 binding to elements in the proximal Arf promoter ( Figure 1A) is enhanced within 1.5 hours following the addition of Tgfb2 to the culture medium, whereas RNA polymerase II (RPolII) binding is not increased until 24 hours, after which Arf mRNA increases [22] . Paralleling the delayed RPolII binding, C/ebpb localization to a proximal promoter element in the Arf promoter was diminished at 24 hours following an initial increase at 1.5 hours ( Figure 1B) . Interestingly, Tgfb stimulation diminished C/ebpb mRNA and protein between 24 and 72 hours ( Figures 1C and D) . The effect on C/ebpb protein expression was evident when it was ectopically expressed ( Figures 2B, lane 3 versus 4) , implying that the decreased repression was not simply due to decreased transcription of the native mRNA. Of note, the fact that p19
Arf level did not strictly inversely correlate with C/ebpb ( Figure 1D, lane 3 versus 1) indicates that other factors, such as cell ''culture shock'' that has been described for cultured mouse fibroblasts [27] , must play a role in expression of this tumor suppressor and these other factors maybe be independent of Tgfb signaling (see more below).
We confirmed that ectopically expressed C/ebpb blunted Arf transcription by showing that b-galactosidase activity was repressed in cultured Arf lacZ/lacZ MEFs infected with retrovirus encoding the liver-enriched activator protein (LAP) isoform of C/ ebpb, which includes a transactivation domain [28, 29] (Figure 2A , Arf expression in cultured MEFs (Figures 2A and B, lane 2 versus 4) . These data indicate that C/ebpb can repress Arf expression in MEFs in a manner that is dominant over Tgfb-dependent induction of p19
Arf .
We next took advantage of C/ebpb 2/2 mice to begin to address whether de-repression by C/ebpb down-regulation contributes to Arf induction by Tgfb. C/ebpb 2/2 mice have been previously shown to exhibit increased postnatal lethality, abnormal hematopoiesis, abnormal glucose homeostasis and immune system defects, among their abnormalities [24, 30] . The mice were generated by introducing a MCI-Neo poly(A)+ mutation at the 39 terminus of C/ebpb to abolish translation of the LAP and LIP isoforms [24] . As previously described [26] , analysis of cultured MEFs derived from wild type and C/ebpb 2/2 embryos demonstrated that basal Arf mRNA and p19
Arf protein were increased upon C/ebpb loss ( Figure 2C Arf protein level. Taken together, these findings indicate that loss of C/ebpb binding to the Arf promoter cannot fully account for the increased Arf mRNA in response to Tgfb stimulation.
We extended our studies to the in vivo setting by examining how the presence or absence of C/ebpb influences Arf expression and Tgfb2 effects in the developing vitreous, the only well-characterized site of p19
Arf activity in the developing mouse embryo [7, 21] . At E13.5, Arf mRNA is principally detected in the primary vitreous ( Figure 3A) , where p19
Arf represses Pdgfrb expression to block vascular mural cell hyperplasia [21, 25] . Consistent with its role as a bona fide repressor, Arf mRNA was elevated in the primary vitreous of C/ebpb 2/2 embryos as compared to wild type ( Figure 3B ). In addition to de-repressing Arf expression in a tissue known to express the transcript, we investigated whether loss of C/ ebpb was sufficient to drive ectopic Arf expression beyond its normal expression pattern. Utilizing Arf lacZ/lacZ animals in which the b-galactosidase reporter reflects Arf mRNA [7] , we did not find enhanced Arf expression in ocular tissues that do not normally express Arf, nor did its expression in genitourinary structures Figure 3C ). Finally, we found no apparent ocular abnormalities at E15.5 or in the postnatal period ( Figure 3D and additional data not shown), indicating that the increased Arf mRNA was not obviously detrimental.
We previously established that p19 Arf expression is diminished in the primary vitreous of Tgfb2 2/2 embryo eyes and this results in primary vitreous hyperplasia, mimicking that observed in Arf 2/2 embryos [7] . That exogenous Tgfb1 reverses this phenotype in Tgfb2 2/2 embryos -but not in Arf 2/2 embryos -demonstrates that p19
Arf is the key Tgfb-dependent target that prevents primary vitreous hyperplasia [22] . If Tgfb2 solely acts to reverse C/ebpbdriven Arf repression, the primary vitreous hyperplasia in Tgfb2 2/2 embryos should be rescued in C/ebpb 2/2 embryos. We investigated this by analyzing the ocular phenotype in Tgfb2 2/2 embryos that had or lacked C/ebpb. Our analyses demonstrated that the eyes of
Tgfb2
2/2 embryos were indistinguishable from those lacking both genes ( Figure 4A and B) . That the absence of an Arf repressor cannot reverse the developmental abnormality illustrates that Tgfb2 likely also influences a positively acting factor to drive p19
Arf expression in the primary vitreous.
Considering potential positive regulators of Arf, E2Fs and Sp1 are reasonable candidates based, in part, on DNA binding elements near the Arf transcription start site ( Figure 1A ). E2Fs have been proven to participate in Arf regulation in various cell contexts [11, 14, 31, 32] . Sp1 has been implied to be important in Arf regulation because deletion of potential Sp1 binding sites diminishes Arf promoter expression, and because Sp1 can bind to the Arf promoter [11, 33] .
To begin to test whether these candidates act in response to Tgfb, we first investigated whether chemical inhibition of either pathway interfered with Arf induction by Tgfb. We utilized Sp1 and C/ebpb Mediate Arf Induction by Tgfb PLOS ONE | www.plosone.orgHLM006474 (HLM), which inhibits the DNA-binding activity of E2Fs [34] , and mithramycin A (MTM) which, among other things, interferes with Sp1 binding to GC-rich DNA [35] . Induction of Arf mRNA by Tgfb proceeded unabated in the absence or presence of HLM ( Figure 5A , lane 3 and 4 versus lane 1 and 2), even though it restored the repression of other E2F-dependent genes like PAI-1 [36] (YZ and SXS, unpublished data). In contrast, MTM blocked Arf mRNA induction ( Figure 5A , land 5 and 6 versus lane 1 and 2), but MTM did not significantly block Smad 2/3 binding to the proximal region of Arf promoter (YZ and SXS, negative data not shown). To exclude potential off-target effects of MTM, we showed that transient Sp1 knockdown by siRNA transfection ( Figure 5B ) also blocked Arf mRNA and protein induction by Tgfb (Figures 5C and D) . Of note, Sp1 knockdown did not block phosphorylation of Smad 2/3 or p38 Mapk ( Figure 5D ), two events that are required downstream of Tgfb2 [22] . Finally, ChIP demonstrated that the minimal Sp1 binding to the proximal Arf promoter at baseline was significantly increased by Tgfb at 24 and 48 hours ( Figure 5E and additional data not shown), paralleling the time course for Arf mRNA increase we previously described [22] . These findings suggest that direct binding of Sp1 to the Arf promoter is required for Tgfb to augment p19
Arf expression.
Discussion
We recently demonstrated that Tgfb is an essential regulator of Arf during eye development [7, 22] . However, Arf expression is limited given the protean effects of Tgfbs during mouse embryo development [7] , and Arf mRNA induction is delayed following immediate Smad 2/3 binding to the promoter [22] . Both suggest that Arf expression is orchestrated by Tgfb-dependent changes in transcriptional regulators beyond the Smad proteins. Our new data indicate that Sp1 and C/ebpb represent such cooperating factors, influencing Arf induction in opposing ways. We have the following evidence: First, ectopic expression of C/ebpb blocked Arf induction by Tgfb. Second, C/ebpb binding to the Arf promoter is diminished by Tgfb treatment in a time frame coincident with Arf mRNA induction. The concept that Tgfb orchestrates derepression of Arf by C/ebpb down-regulation in vivo is supported by the fact that Arf expression in the vitreous is elevated in C/ebpb 2/2 animals. However, absent the essential Arf inducer -Tgfb2-loss of C/ebpb is not sufficient to correct the PHPV-like eye phenotype in Tgfb2 2/2 mice; hence, removing C/ebpb repression is not the whole story. Searching for a positive trans-acting factor induced by Tgfb, we found chemical and genetic evidence supporting a role for Sp1. In summary, our data provide new insight into the molecular basis underlying Arf control by Tgfb during eye development, and this may inform our understanding of certain disease processes.
Our work extends previous reports implicating both C/ebpb and Sp1 as potential regulators of p19
Arf expression. That C/ebpb can repress Arf was previously suggested primarily by the elevated Arf mRNA and protein observed in C/ebpb 2/2 keratinocytes in culture and in the adult mouse [26] . Sp1 is well known to bind to GC-rich promoter elements [37, 38] , and the mouse and human Arf promoters contain numerous Sp1 binding sites within CpG islands [15, 33] . Several previous studies showed the potential importance of Sp1 binding to the human ARF promoter in cultured cells [11, 39] . However, the potential physiological importance of either in Arf regulation is not yet clear. For example, C/ebpb 2/2 mice are completely refractory to chemically induced skin cancer [40] , which concept is consistent with higher p19
Arf expression as a tumor suppressor. However, Arf does not seem to play a role in tumor resistance in this model [26] . Nonetheless, our findings demonstrating increased Arf mRNA in the vitreous of C/ebpb 2/2 embryos indicates that C/ebpb can repress Arf in a normal developmental context. The lack of widespread Arf promoter activation in these embryos and newborn Arf lacZ/lacZ , C/ebpb 2/2 mice, though, still highlights the importance of tissue-specific positive transcriptional regulators of Arf.
The fact that the phenotype due to blunted Arf expression in Tgfb2-deficent embryo eyes was not reversed in animals also lacking C/ebpb provides additional in vivo evidence for the importance of positively-acting factors. That Sp1 cooperates with Smad signaling is consistent with previous findings that Tgfb2 regulates p15
Ink4b through direct Sp1 binding to the promoter [41, 42] . Sp1 also collaborates with Smad proteins to induce the expression of vimentin in cultured cells undergoing the epithelialmesenchymal transition in response to Tgfb [43] . Our preliminary work shows that decreased expression of C/ebpb in response to Tgfb depends on TbrII and Smad 2/3 activation (YZ and SXS, unpublished data), but we do not yet know whether Sp1 binding to the Arf promoter similarly depends on the activation of that pathway. Sp1 is also known to work cooperatively with E2Fs [44] , which are also implicated as both positive and negative regulators of Arf [11, 31, 32, 45] . Our finding that HLM does not significantly block Arf induction by Tgfb suggests that Sp1 seems to act independently of E2Fs in this context. It will obviously be important to demonstrate the functional importance of Sp1 in vivo using our mouse model for PHPV. Regrettably, Sp1 2/2 mice display an embryonic lethal phenotype at E11.5, before primary vitreous development [46] . Tissue specific Sp1 knockout using a Wnt1-Cre driver would be very informative.
Finally, we have carried out this line of investigation in the mouse to gain insight into human diseases, like cancer and PHPV. Repression of human ARF expression is a relatively common mechanism by which cancers can evade this tumor suppressor activity [47] ; presumably, restoring ARF expression could represent a novel therapeutic approach, especially for that subset of cancers also retaining wild type p53. As a human disease, PHPV is typically sporadic, but several reports of familial disease suggest that it could have an underlying genetic basis [48, 49, 50] . C/ebpb is frequently expressed in human cancer and has been implicated as an oncogenic factor (as in the keratinocyte model noted above) [26, 40] or tumor suppressor with the capacity to foster senescence [51, 52] . These disparate effects may be due, in part, to the capacity of C/ebpb to form homo-and heterodimeric complexes with either activating or transcriptional repressive activity [28] . Sp1, too, could act as a Tgfb-dependent tumor suppressor, by controlling Ink4b [41, 42] or Arf (this work), or as an oncogene by facilitating EMT [43] . Again, one could envision that the net effect of Sp1 could depend on the underlying cellular or genetic context. As more sophisticated, ''next-generation'' genome sequencing and analytical tools are applied -particularly to diseases like PHPVthe role for these genes might be revealed.
